Intracerebroventricular Administration of Neuropeptide Y Induces Hepatic Insulin Resistance via Sympathetic Innervation by van den Hoek, Anita M. et al.
Intracerebroventricular Administration of Neuropeptide
Y Induces Hepatic Insulin Resistance via Sympathetic
Innervation
Anita M. van den Hoek,
1 Caroline van Heijningen,
2 Janny P. Schro ¨der-van der Elst,
3
D. Margriet Ouwens,
4 Louis M. Havekes,
1,3,5,6 Johannes A. Romijn,
3 Andries Kalsbeek,
2 and
Hanno Pijl
3
OBJECTIVE—We recently showed that intracerebroventricular
infusion of neuropeptide Y (NPY) hampers inhibition of endog-
enous glucose production (EGP) by insulin in mice. The down-
stream mechanisms responsible for these effects of NPY remain
to be elucidated. Therefore, the aim of this study was to establish
whether intracerebroventricular NPY administration modulates
the suppressive action of insulin on EGP via hepatic sympathetic
or parasympathetic innervation.
RESEARCH DESIGN AND METHODS—The effects of a con-
tinuous intracerebroventricular infusion of NPY on glucose turn-
over were determined in rats during a hyperinsulinemic-
euglycemic clamp. Either rats were sham operated, or the liver
was sympathetically (hepatic sympathectomy) or parasympa-
thetically (hepatic parasympathectomy) denervated.
RESULTS—Sympathectomy or parasympathectomy did not af-
fect the capacity of insulin to suppress EGP in intracerebroven-
tricular vehicle–infused animals (50  8 vs. 49  6 vs. 55  6%,
in hepatic sympathectomy vs. hepatic parasympathectomy vs.
sham, respectively). Intracerebroventricular infusion of NPY
signiﬁcantly hampered the suppression of EGP by insulin in
sham-denervated animals (29  9 vs. 55  6% for NPY/sham vs.
vehicle/sham, respectively, P  0.038). Selective sympathetic
denervation of the liver completely blocked the effect of intrace-
rebroventricular NPY administration on insulin action to sup-
press EGP (NPY/hepatic sympathectomy, 57  7%), whereas
selective parasympathetic denervation had no effect (NPY/he-
patic parasympathectomy, 29  7%).
CONCLUSIONS—Intracerebroventricular administration of
NPY acutely induces insulin resistance of EGP via activation of
sympathetic output to the liver. Diabetes 57:2304–2310, 2008
S
ince Claude Bernard ﬁrst observed in the 1850s
that puncture of the ﬂoor of the fourth cerebral
ventricle elevates blood glucose levels, the fun-
damental role of the brain in the control of
glucose metabolism has been ﬁrmly established (1,2).
Intracerebroventricular infusion of insulin inhibits endog-
enous glucose production (EGP) (3), and downregulation
of hypothalamic insulin receptors by antisense oligonucle-
otides precludes suppression of EGP by (circulating)
insulin to a considerable extent (4). Thus, hypothalamic
insulin signaling appears to play a role in the control of
EGP. Insulin inhibits neuropeptide Y (NPY)-producing
neurons in the arcuate nucleus of the hypothalamus (5).
Intracerebroventricular administration of NPY hampers
the capacity of insulin to suppress EGP (6), suggesting that
silencing of arcuate NPY neurons may contribute to the
inhibitory effect of intracerebroventricular insulin admin-
istration on EGP.
The downstream mechanism responsible for the effects
of hypothalamic NPY on hepatic fuel ﬂux remains to be
established. Arcuate NPY neurons project to the paraven-
tricular nucleus (PVN) and various other hypothalamic
nuclei (7). The hypothalamus is a major source of fore-
brain input into the sympathetic nervous system (8); it
partakes in the control of cholinergic outﬂow to visceral
organs (9,10), and it orchestrates the release of various
pituitary hormones (11,12). Either of these neuroendo-
crine systems can impact on EGP (13–15).
Here, we test the hypothesis that intracerebroventricu-
lar administration of NPY hampers the ability of insulin to
suppress EGP via autonomic nervous inputs to the liver.
To this end, rats whose livers were selectively stripped of
sympathetic or parasympathetic nerves received intrace-
rebroventricular infusion of NPY or vehicle. The capacity
of insulin to inhibit EGP was quantiﬁed by hyperinsuline-
mic-euglycemic clamp.
RESEARCH DESIGN AND METHODS
Male Wistar rats (Harlan Nederland, Horst, the Netherlands) were housed in
a temperature-controlled room on a 12-h light-dark cycle with lights on at 7:00
A.M. Food and water were available ad libitum, except during experimental
sessions, when only water was available. Animals weighed between 260 and
340 g at the time of the experiments. All animal experiments were performed
in accordance with the regulations of Dutch law on animal welfare, and the
institutional ethics committee for animal procedures approved the protocol.
Surgical procedures. Rats were anesthetized with 0.08 ml/100 g body wt i.m.
Hypnorm (Janssen Pharmaceutica, Beerse, Belgium) and 0.04 ml/100 g body
wt s.c. Dormicum (Genthon, Nijmegen, the Netherlands). Postoperative care
was provided with a subcutaneous injection of 30 l/100 g body wt 1:10
Fynadine (Dopharma, Raamsdonksveer, the Netherlands). All animals re-
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2304 DIABETES, VOL. 57, SEPTEMBER 2008ceived two permanent catheters for infusion and blood sampling and under-
went stereotaxic surgery. The liver was selectively stripped of its sympathetic
or parasympathetic nerves, or a sham operation was performed. After a
recovery period of 1 week, hyperinsulinemic-euglycemic clamp experiments
were performed.
Hepatic sympathectomy. Hepatic sympathectomy was performed as previ-
ously described (16,17). A left-to-right incision was performed in the midline.
The liver lobes were gently pushed up, and ligaments around the liver lobes
were severed to free the bile duct and portal vein complex, which were
isolated from each other. At the level of the hepatic portal vein, the hepatic
artery breaks up into the hepatic artery proper and the gastroduodenal artery.
This division occurs on the ventral surface of the portal vein. At this point, the
arteries were separated via blunt dissection from the portal vein. Nerve
bundles running along the hepatic artery proper were removed using micro-
surgical instruments under an operating microscope (magniﬁcation 25). Any
connective tissue attachments between the hepatic artery and portal vein
were also broken, eliminating any possible nerve crossings. This procedure
does not impair the vagal input to the liver, as shown previously (16).
Hepatic parasympathectomy. Hepatic parasympathectomy was performed
as previously described (16). In short, a left-to-right incision was performed in
the midline. The fascia containing the hepatic branch was stretched by gently
moving the stomach and the esophagus. With the aid of a binocular-operating
microscope, the neural tissue was transected between the ventral vagus trunk
and liver. Also, small branches running in the fascia between the stomach and
the liver were transected. We also dissected the nerves running over the
stomach to the left lobe of the liver as described by Magni and Carobi (18).
Particular care was taken not to damage the dorsal and ventral trunks
innervating the stomach and abdominal tissues or blood vessels that run along
the hepatic vagus branches.
Veriﬁcation of liver denervation. From previous studies, we knew that the
success rate of sympathetic denervation of the liver may be 100%, whereas
hepatic parasympathetectomy is easier and always accurate (17). Therefore,
we checked the completeness of the sympathectomy by comparing hepatic
norepinephrine concentrations in both sympathectomized groups with those
in the sham-operated group receiving vehicle. After the experimental proce-
dures, liver aliquots were processed and analyzed using a commercially
available norepinephrine radioimmunoassay (RIA) (RE29325; IBL-Hamburg,
Hamburg, Germany). Tissue samples were homogenized in ice-cold 0.1 N HCL
and 1 mmol EDTA solution (1 ml/50 mg wet tissue) and centrifuged at 13,000
rpm for 15 min at 4°C. Samples of 200 l supernatant were transferred to the
extraction plate of the RIA kit, and bidest was added to a ﬁnal volume of 1 ml.
A RIA was then performed according to the manufacturer’s protocol.
Norepinephrine levels were profoundly decreased in all but one of the
sympathectomized animals (hepatic norepinephrine levels, 0.53  0.06 vs.
0.14  0.08 vs. 0.03  0.02 ng/mg protein in vehicle/sham, vehicle/hepatic
sympathectomy, and NPY/hepatic sympathectomy, respectively). The results
obtained in one animal (which received vehicle) were not included in our
analysis, because the norepinephrine concentration in its liver did not show a
clear reduction compared with the sham-operated animals, indicating incom-
plete sympathectomy.
Placement of catheters. Rats were provided with two permanent catheters
of sterile silicon. One was inserted into the right jugular vein for infusion of
ﬂuids and one into the left carotid artery for blood sampling. Both catheters
were attached to bent steel tubings that were ﬁxed on top of the rat skulls by
means of four stainless-steel screws and dental cement.
Stereotaxic surgery. A cannula was implanted into the left lateral ventricle
using the following coordinates from Bregma: 0.8 mm posterior, 2.0 mm
lateral, and 3.2 mm ventral. Dental cement and four screws were used to ﬁx
the cannula onto the skull.
Experimental procedures. Animals were divided in six different groups:
intracerebroventricular vehicle-infused sham-operated animals (n  7), vehi-
cle-infused hepatic sympathectomized animal (n  5), vehicle-infused hepatic
parasympathectomized animals (n  6), NPY-infused sham-operated animals
(n  7), NPY-infused hepatic sympathectomized animals (n  7), and
NPY-infused hepatic parasympathectomized animals (n  7). During the
experiments, the input port of the intracerebroventricular cannula and the
jugular vein catheter were connected to remote syringes via a double-ﬂuid
swivel interconnected with polyethylene tubing. This allowed all manipula-
tions to be performed outside the cages without touching the animals. The rats
were connected 1 day before the actual experiment to familiarize them with
the experimental setup. The night preceding the experiment, animals were fed
normally until 8:00 A.M., when food was removed and the output port of the
carotid artery catheter was connected to polyethylene tubing. From 8:30 to
11:00 A.M., the intracerebroventricular infusion was started to empty the
dead space in the tubing between the ﬂuid swivel and intracerebroventric-
ular cannula. As of 11:00 A.M., hyperinsulinemic-euglycemic clamps were
performed as described previously (19). At 11:00 A.M., 10 g/h intracere-
broventricular NPY (dose based on prior experiments documenting effects
on EGP in mice; Bachem, Bubendorf, Switzerland) (6) and vehicle infu-
sions were started at a rate of 5 l/h until the end of the experiments. First,
a primed (1-Ci) continuous (7-Ci/h) infusion of [
3H]glucose (Amersham,
Little Chalfont, U.K.) was given for 75 min for determination of basal rates
of glucose turnover. Subsequently, insulin was administered in a primed
(10-mU) continuous (62.5-mU/h) intravenous infusion for2ht oattain
steady-state circulating insulin levels of 5.3 ng/ml. A variable infusion of
25% D-glucose was used to maintain euglycemia (measured at 10-min
intervals) (Freestyle; TheraSense, Disetronic Medical Systems, Vianen, the
Netherlands). Blood samples (200 l) were taken during the basal period
(at 60 and 75 min after the start of NPY or vehicle infusion) and during the
clamp period (at 90, 105, and 120 min after the start of insulin infusion) for
determination of plasma glucose, insulin, glucagon, corticosterone, and
[
3H]glucose speciﬁc activities. At the end of the experiments, animals were
killed, and tissue samples were taken and frozen in liquid nitrogen for
subsequent analysis.
Analytical procedures. Plasma levels of glucose, insulin, glucagon, cortico-
sterone, T3, T4, and testosterone were measured by a commercially available
kit, an insulin ELISA, glucagon RIA, corticosterone ELISA, T3 and T4 ELISA,
and testosterone ELISA (Instruchemie, Delfzijl, the Netherlands; Mercodia,
Uppsala, Sweden; Euro-diagnostica, Malmo ¨, Sweden; Lucron Bioproduct, De
Pinte, Belgium; IDS, Boldon, U.K.; Endocrine Technologies, Newark, NJ [T3,
T4, and testosterone], respectively). Total plasma [
3H]glucose was determined
in 7.5 l plasma and in supernatants after trichloroacetic acid (20%) precipi-
tation and water evaporation to eliminate tritiated water.
Calculations. Turnover rates of glucose (mol  min
1  kg
1) were calcu-
lated during the basal period and in steady-state clamp conditions as the rate
of tracer infusion (dpm/min) divided by the plasma speciﬁc activity of
[
3H]glucose (dpm/mol). The ratio was corrected for body weight. EGP was
calculated as the difference between the tracer-derived rate of glucose
appearance and the glucose infusion rate.
Statistical analysis. Differences between groups were ﬁrst determined by
Kruskal-Wallis nonparametric tests for multiple independent samples. Subse-
quently, differences between each group in comparison with the vehicle sham
group were determined by Mann-Whitney nonparametric tests for indepen-
dent samples. A P value 0.05 was considered statistically signiﬁcant. All
values shown represent means  SE.
TABLE 1
Plasma parameters 1
Glucose (mmol/l) Insulin (ng/ml) Glucagon (pmol/l)
Basal Hyperinsulinemic Basal Hyperinsulinemic Basal Hyperinsulinemic
Vehicle/sham 7.3  0.5 6.7  0.3 2.2  0.2 4.2  0.5 53.4  5.8 46.0  7.7
Vehicle/hepatic sympathectomy 5.9  0.3* 6.4  0.4 3.1  0.8 4.5  0.4 68.2  8.1 33.7  4.8
Vehicle/hepatic parasympathectomy 7.7  0.5 6.5  0.3 2.9  0.7 6.2  1.0 48.3  7.3 35.3  6.1
NPY/sham 6.2  0.3 7.0  0.4 2.7  0.8 6.4  1.0 60.3  11.5 43.1  8.3
NPY/hepatic sympathectomy 6.5  0.2 6.3  0.3 2.9  0.4 5.4  0.7 60.8  6.1 38.9  8.2
NPY/hepatic parasympathectomy 7.6  0.5 7.2  0.1 3.0  0.7 4.9  0.6 63.0  5.8 48.3  5.1
Data are means  SE for at least ﬁve rats per group. Plasma glucose, insulin, and glucagon concentrations under basal or hyperinsulinemic
conditions in rats that received an intracerebroventricular infusion of NPY or vehicle and of which the liver was sympathetically (hepatic
sympathectomy) denervated, parasympathetically (hepatic parasympathectomy) denervated, or sham operated. *P  0.05 vs. vehicle sham.
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Plasma parameters. Plasma glucose, insulin, glucagon,
corticosterone, T3, T4, and testosterone concentrations in
basal and hyperinsulinemic conditions are shown in Ta-
bles 1 and 2. Plasma glucose and insulin levels were similar
in all groups, both in basal and hyperinsulinemic conditions,
except for basal glucose concentrations, which were signiﬁ-
cantly (P  0.048) lower in sympathectomized animals
receiving vehicle. Insulin infusion reduced plasma glucagon,
T3, and testosterone levels, but the circulating concentra-
tions of none of these hormones were different between
groups within basal or hyperinsulinemic conditions.
Basal glucose turnover. In basal conditions, glucose
turnover (reﬂecting EGP) was not affected by NPY admin-
istration. Parasympathetic denervation of the liver signif-
icantly increased basal glucose turnover, whereas
sympathetic denervation had no effect (vehicle/sham, 83 
6 mol  min
1  kg
1; vehicle/hepatic sympathectomy,
81  7 mol  min
1  kg
1; vehicle/hepatic parasympa-
thectomy, 101  5 mol  min
1  kg
1 [P  0.017 vs.
vehicle/sham]; NPY/sham, 91  12 mol  min
1  kg
1;
NPY/hepatic sympathectomy, 75  7 mol  min
1  kg
1;
and NPY/hepatic parasympathectomy, 116  10 mol 
min
1  kg
1 [P  0.008 vs. vehicle/sham]; Fig. 1).
Insulin-mediated glucose metabolism. The rate of glu-
cose infusion necessary to maintain euglycemia during
insulin infusion is shown in Fig. 2. Neither sympathectomy
nor parasympathectomy affected the glucose infusion rate
in animals receiving vehicle (hepatic sympathectomy,
72  6 mol  min
1  kg
1; hepatic parasympathectomy,
73  4 mol  min
1  kg
1; and sham, 71  5 mol  min
1 
kg
1). Intracerebroventricular NPY infusion clearly reduced
the glucose infusion rate required to maintain euglycemia in
sham-denervated animals, reﬂecting the induction of insulin
resistance by NPY (NPY/sham, 49  5 mol  min
1  kg
1;
P  0.007 vs. vehicle/sham). Hepatic sympathectomy com-
pletely abolished this effect of NPY on the glucose infusion
rate (NPY/hepatic sympathectomy, 65  5 mol  min
1 
kg
1; NS vs. vehicle/sham), whereas the inhibitory impact of
NPY on glucose infusion remained unabated in parasympa-
thectomized animals (NPY/hepatic parasympathectomy,
52  6 mol  min
1  kg
1; P  0.007 vs. vehicle/sham).
Insulin-mediated glucose disposal was similar in all
groups (vehicle/sham, 110  7 mol  min
1  kg
1;
vehicle/hepatic sympathectomy, 111  6 mol  min
1 
kg
1; vehicle/hepatic parasympathectomy, 125  6 mol 
min
1  kg
1; NPY/sham, 119  11 mol  min
1  kg
1;
NPY/hepatic sympathectomy, 98  5 mol  min
1  kg
1;
and NPY/hepatic parasympathectomy, 134  11 mol 
min
1  kg
1; Fig. 3A).
The suppression of EGP by insulin is shown in Fig. 3B.
Hepatic sympathectomy or hepatic parasympathectomy
did not impact on the capacity of insulin to suppress EGP
in animals receiving vehicle (vehicle/sham, 55  6%;
vehicle/hepatic sympathectomy, 52  9%; and vehicle/
hepatic parasympathectomy, 49  6%). Intracerebroven-
tricular NPY infusion signiﬁcantly hampered the inhibitory
action of insulin on EGP in sham-denervated animals
(NPY/sham, 29  9%; P  0.038 vs. vehicle/sham). Hepatic
sympathectomy completely abolished the effect of NPY on
EGP (NPY/hepatic sympathectomy, 57  7%; NS vs. vehi-
cle/sham), whereas the inhibitory impact of NPY on the
suppression of EGP remained unabated in parasympathec-
tomized animals (NPY/hepatic parasympathectomy, 29 
7%; P  0.017 vs. vehicle/sham).
T
A
B
L
E
2
P
l
a
s
m
a
p
a
r
a
m
e
t
e
r
s
2
C
o
r
t
i
c
o
s
t
e
r
o
n
e
(
n
g
/
m
l
)
T
3
(
n
g
/
m
l
)
T
4
(
n
g
/
m
l
)
T
e
s
t
o
s
t
e
r
o
n
e
(
n
g
/
m
l
)
B
a
s
a
l
H
y
p
e
r
i
n
s
u
l
i
n
e
m
i
c
B
a
s
a
l
H
y
p
e
r
i
n
s
u
l
i
n
e
m
i
c
B
a
s
a
l
H
y
p
e
r
i
n
s
u
l
i
n
e
m
i
c
B
a
s
a
l
H
y
p
e
r
i
n
s
u
l
i
n
e
m
i
c
V
e
h
i
c
l
e
/
s
h
a
m
2
5
.
7

7
.
6
2
3
.
0

5
.
5
1
.
8

0
.
3
1
.
1

0
.
2
4
3
.
5

3
.
9
4
9
.
6

9
.
5
0
.
4
1

0
.
0
9
0
.
2
4

0
.
0
8
V
e
h
i
c
l
e
/
h
e
p
a
t
i
c
s
y
m
p
a
t
h
e
c
t
o
m
y
2
5
.
3

1
2
.
3
1
6
.
8

5
.
8
2
.
0

0
.
4
1
.
4

0
.
2
5
2
.
5

8
.
4
4
1
.
4

3
.
5
0
.
6
5

0
.
1
6
0
.
2
0

0
.
1
0
V
e
h
i
c
l
e
/
h
e
p
a
t
i
c
p
a
r
a
s
y
m
p
a
t
h
e
c
t
o
m
y
4
4
.
2

2
.
6
2
5
.
9

5
.
1
1
.
3

0
.
2
1
.
3

0
.
3
6
3
.
4

4
.
4
5
5
.
3

6
.
4
0
.
6
6

0
.
2
0
*
0
.
3
2

0
.
1
0
*
N
P
Y
/
s
h
a
m
2
8
.
2

5
.
9
3
1
.
5

5
.
1
1
.
8

0
.
2
1
.
1

0
.
2
5
7
.
0

6
.
8
5
1
.
5

5
.
9
0
.
6
6

0
.
1
5
0
.
1
5

0
.
0
5
N
P
Y
/
h
e
p
a
t
i
c
s
y
m
p
a
t
h
e
c
t
o
m
y
2
9
.
7

4
.
6
2
6
.
9

7
.
8
1
.
9

0
.
4
1
.
0

0
.
3
4
9
.
6

4
.
1
5
2
.
8

4
.
1
0
.
7
1

0
.
2
2
0
.
3
7

0
.
1
5
N
P
Y
/
h
e
p
a
t
i
c
p
a
r
a
s
y
m
p
a
t
h
e
c
t
o
m
y
3
9
.
9

2
.
3
3
2
.
3

2
.
1
1
.
3

0
.
3
1
.
4

0
.
4
4
6
.
7

2
.
9
6
8
.
6

1
4
.
0
0
.
3
9

0
.
0
9
0
.
1
8

0
.
0
2
D
a
t
a
a
r
e
m
e
a
n
s

S
E
f
o
r
a
t
l
e
a
s
t
ﬁ
v
e
r
a
t
s
p
e
r
g
r
o
u
p
.
P
l
a
s
m
a
c
o
r
t
i
c
o
s
t
e
r
o
n
e
,
T
3
,
T
4
,
a
n
d
t
e
s
t
o
s
t
e
r
o
n
e
c
o
n
c
e
n
t
r
a
t
i
o
n
s
u
n
d
e
r
b
a
s
a
l
o
r
h
y
p
e
r
i
n
s
u
l
i
n
e
m
i
c
c
o
n
d
i
t
i
o
n
s
i
n
r
a
t
s
t
h
a
t
r
e
c
e
i
v
e
d
a
n
i
n
t
r
a
c
e
r
e
b
r
o
v
e
n
t
r
i
c
u
l
a
r
i
n
f
u
s
i
o
n
o
f
N
P
Y
o
r
v
e
h
i
c
l
e
a
n
d
o
f
w
h
i
c
h
t
h
e
l
i
v
e
r
w
a
s
s
y
m
p
a
t
h
e
t
i
c
a
l
l
y
(
h
e
p
a
t
i
c
s
y
m
p
a
t
h
e
c
t
o
m
y
)
d
e
n
e
r
v
a
t
e
d
,
p
a
r
a
s
y
m
p
a
t
h
e
t
i
c
a
l
l
y
(
h
e
p
a
t
i
c
p
a
r
a
s
y
m
p
a
t
h
e
c
t
o
m
y
)
d
e
n
e
r
v
a
t
e
d
,
o
r
s
h
a
m
o
p
e
r
a
t
e
d
.
*
T
h
e
s
e
d
a
t
a
a
r
e
b
a
s
e
d
o
n
f
o
u
r
(
b
a
s
a
l
)
a
n
d
t
h
r
e
e
(
h
y
p
e
r
i
n
s
u
l
i
n
e
m
i
c
)
r
a
t
s
o
n
l
y
a
n
d
t
h
e
r
e
f
o
r
e
m
u
s
t
b
e
c
o
n
s
i
d
e
r
e
d
w
i
t
h
c
a
u
t
i
o
n
.
NPY AFFECTS EGP VIA SYMPATHETIC INNERVATION
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Here, we report that selective hepatic sympathectomy
completely reverses the deleterious effect of intracerebro-
ventricular NPY administration on the capacity of insulin
to inhibit EGP in Wistar rats. In contrast, selective destruc-
tion of parasympathetic nerves innervating the liver does
not modify the impact of NPY on hepatic insulin sensitiv-
ity. These data corroborate previous ﬁndings in rats and
mice, demonstrating that intracerebroventricular adminis-
tration of NPY hampers insulin action to inhibit glucose
and VLDL production (6,20). The present results suggest
that NPY neurons modulate this inhibitory effect of insulin
on glucose production via efferent sympathetic nerves
innervating the liver.
The role of the autonomic nervous system in the control
of glucose metabolism is well established. The liver is
densely innervated by sympathetic and parasympathetic
nerves that can be traced back to the PVN (16,21).
Activation of sympathetic nerves stimulates glycogen
phosphorylase and inhibits glycogen synthase, thereby
increasing glycogen breakdown and glucose production.
In contrast, parasympathetic activation enhances glucose
uptake by the liver (13). Neurons in control of sympathetic
and parasympathetic nerves innervating the liver were
identiﬁed in various hypothalamic nuclei by viral tracing
technology (16). The hypothalamus is critically involved in
the control of autonomic outﬂow to various tissues (8–10),
it contains many neurons expressing NPY receptors in
various nuclei (22), and these receptors are involved in the
control of autonomic activity. NPY injection into the third
cerebral ventricle primarily impacts adjacent hypotha-
lamic nuclei, including the PVN and the supraoptic nuclei
(23), which exert differential effects on sympathetic out-
ﬂow on NPY administration (24). Precise identiﬁcation of
the speciﬁc neurons and nuclei involved in the effects of
NPY administration observed here requires further study.
Hypothalamic NPY neurons are involved in the control
of pituitary hormone release, but our ﬁndings argue
against the possibility that the acute effects of NPY on
insulin action in the liver are mediated by endocrine cues.
For example, NPY inhibits growth hormone secretion (25)
and stimulates the activity of the pituitary-adrenal ensem-
ble (26). Corticosteroids clearly promote glucose produc-
tion (27,28), and adrenalectomy was shown to prevent or
reduce at least some of the metabolic effects of subchronic
intracerebroventricular NPY administration, i.e., hyperpha-
gia, weight gain, and hyperinsulinemia (26,29,30). Intracere-
broventricular NPY infusion for 5–7 days in rats was
shown to decrease plasma IGF-1 and testosterone levels,
endocrine cues well known for their effect on insulin
action (31). However, NPY did not affect circulating levels
of corticosterone, testosterone, glucagon, or thyroid hor-
mones (T3 and T4) in the current experimental context.
Moreover, the impact of NPY on insulin action was com-
pletely abolished by selective hepatic sympathectomy. In
aggregate, the data suggest that the acute metabolic effects
of central NPY administration are primarily caused by
activation of sympathetic nerves innervating the liver,
whereas the pituitary-adrenal ensemble and other endo-
crine cues may be engaged by more prolonged adminis-
tration of NPY.
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FIG. 1. Basal glucose turnover. Basal glucose turnover in rats that were
sham operated or in which the liver was sympathetically (HSx) or
parasympathetically (HPx) denervated and that received an intracere-
broventricular infusion of NPY or vehicle. Values are means  SE for at
least ﬁve animals per group. *P < 0.05 vs. vehicle sham group.
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FIG. 2. Glucose infusion rate. Glucose infusion rate (GIR) in rats that
were sham operated or in which the liver was sympathetically (HSx) or
parasympathetically (HPx) denervated and that received an intracere-
broventricular infusion of NPY or vehicle during a hyperinsulinemic-
euglycemic clamp. Values are means  SE for at least ﬁve animals per
group. *P < 0.05 vs. vehicle sham group.
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FIG. 3. Insulin-mediated glucose disposal and inhibition of EGP by
insulin. Insulin-mediated glucose disposal (A) and inhibition of EGP by
insulin (B) in rats that were sham operated or in which the liver was
sympathetically (HSx) or parasympathetically (HPx) denervated and
that received an intracerebroventricular infusion of NPY or vehicle
during a hyperinsulinemic-euglycemic clamp. Values are means  SE
for at least ﬁve animals per group. *P < 0.05 vs. vehicle sham group.
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creased EGP in the basal condition, whereas selective
sympathectomy had no effect. This corroborates a previ-
ous report, documenting an increase of basal glucose
production after parasympathetic denervation of the liver
in rats (32). Conversely, parasympathetic activation by
electrical stimulation of the hepatic nerve inhibits glucose
production in cats (33). Thus, an increase of EGP in
parasympathectomized animals may be explained by a
predominance of sympathetic inputs to the liver in the
absence of parasympathetic activity. Pocai et al. (34) have
shown that intracerebroventricular infusion of insulin
inhibits hepatic glucose production via hepatic vagal ef-
ferents. In particular, their data suggest that hepatic va-
gotomy negates the inhibitory impact of central insulin
infusion on glucose production and halves the effect of
systemic administration. In apparent contrast, hepatic
parasympathectomy did not affect the capacity of insulin
to suppress EGP in the current experimental context. The
present ﬁnding is in agreement with another recent study
of our group (35). As discussed in that paper, the contrast
between the study of Pocai et al. and ours may relate to the
lower level of peripheral hyperinsulinemia attained in our
studies. For the effect of hepatic vagotomy to become
apparent, insulin may have to be administered centrally, or
peripheral insulin levels should be increased to such an
extend that hepatic glucose production is inhibited 80%.
We show that NPY hampers insulin action to inhibit
EGP via activation of sympathetic outﬂow to the liver. In
fasting conditions, low circulating insulin levels allow
expression of NPY in the hypothalamus, activating sympa-
thetic outﬂow to the liver, which in its turn induces hepatic
insulin resistance to maximize EGP. In the fed state, when
high plasma insulin levels inhibit hypothalamic NPY ex-
pression, parasympathetic outﬂow to the liver prevails to
inhibit glucose production. The fact that parasympathec-
tomy did not impair the capacity of insulin to suppress
EGP in intracerebroventricular vehicle–infused animals in
the present study is in apparent contrast with this sce-
nario. However, although parasympathectomy did not
signiﬁcantly affect the relative decline of EGP during
hyperinsulinemia (Fig. 3B), it did increase the absolute
rate of glucose production in hyperinsulinemic condition.
In this respect, it is important to point out that parasym-
pathectomy enhanced basal glucose production in the
current experimental context, which is also counterintui-
tive in light of the fact that NPY expression and sympa-
thetic activity are supposed to be elevated in fasting
animals. However, our subjects fasted for only 4 h before
the studies, because we wanted NPY levels to be low in
vehicle-treated rats to maximize the contrast with NPY
treated animals. Thus, parasympathetic tone may have
dominated in basal conditions in our studies, explaining
the fact that hepatic parasympathectomy increased EGP.
The present study shows that administration of NPY
into the lateral ventricle modulates the inhibitory effect of
insulin on glucose production via activation of sympa-
thetic output to the liver. Intracerebroventricular NPY
injection also enhances sympathetic tone in vascular beds
of heart, splanchnic tissues, and skeletal muscle (36). In
contrast, in brown adipose tissue, it appears to inhibit
sympathetic tone, and it activates parasympathetic out-
ﬂow to the pancreas (24,37). NPY therefore seems to exert
differential effects on autonomic output to various tissues,
analogous to what is known about other peptides like
leptin and cholecystokinin (38–40).
What are the potential (patho)physiological implications
of these ﬁndings? NPY neuronal activity in the arcuate
nucleus is governed by a variety of hormones and metab-
olites reﬂecting energy availability. Cues reﬂecting a state
of plenty (i.e., leptin, insulin, gut-peptides, and glucose)
inhibit NPY neurons (41–43). Circulating levels of these
cues are low in the fasting state, which unleashes arcuate
NPY release. Activation of sympathetic outﬂow to the liver
by NPY subsequently induces insulin resistance of glucose
production, facilitating glucose output, which is required
for fostering the brain in the absence of food. In the
context of chronic overfeeding, NPY gene expression in
the arcuate nucleus is paradoxically elevated, probably as
a result of insulin and leptin resistance of arcuate neurons
(44,45). There is also substantial evidence of leptin resis-
tance in obese humans (46), and myriad data support the
contention that the sympathetic nervous system is exceed-
ingly active in subjects with the metabolic syndrome
(47–49 and references therein). Several of the components
of the metabolic syndrome, like hypertension, obesity, and
insulin resistance, are associated with adrenergic over-
drive. In contrast, it has also been reported that the
response of the sympathetic nervous system to various
stimuli is diminished in obese humans (47–49), However,
most investigators agree that obesity is marked by en-
hanced sympathetic tone in most tissues, at least in the
basal state (47–49 and references therein). Our data
suggest that elevation of hypothalamic NPY levels as a
corollary of leptin resistance may contribute to sympa-
thetic overdrive, hepatic insulin resistance, and increased
glucose production in high-fat–fed rodents and man. If so,
it is conceivable that selective (ant)agonism of speciﬁc
NPY receptors can ameliorate hyperglycemia in obese
individuals.
NPY affects a wide variety of physiological processes via
distinct NPY receptors. The Y1, Y2, Y4, and Y5 receptor are
involved in regulating food intake and/or energy expendi-
ture. Blocking the Y1 or Y5 receptor and stimulation of the
Y2 or Y4 receptor inhibits food intake. Hence, Y1 and Y5
antagonists and Y2 and Y4 agonists have been tested in
experimental studies for the treatment of obesity and
related diseases (rev. in 50,51). Intracerebroventricular
and oral administration of the Y1 antagonist J-115814
suppresses feeding and induces sustained body weight
loss in obese Zucker fatty rats. Y5 antagonists and Y2 or Y4
agonists have similar effects (rev. in 50). It is currently
unknown which NPY receptor subtype(s) is involved in
the control of metabolic processes. However, a recent
study by Singhal et al. (52) indicates that the Y1 receptor
might be important in this respect. Because it makes sense
to assume that the mechanisms regulating food intake and
metabolism are tightly coupled, it is reasonable to propose
that any one of the receptors involved in the control of
food intake simultaneously modulates EGP. However, this
issue requires further study, particularly because identiﬁ-
cation of NPY receptor subtypes involved in metabolic
control may pave the way for pharmacotherapy with NPY
receptor (ant)agonists in patients with type 2 diabetes.
In conclusion, the present study shows that intracere-
broventricular administration of NPY in rats acutely ham-
pers the capacity of insulin to suppress EGP via activation
of sympathetic nerves innervating the liver. Our data may
provide an explanation for the sympathetic overdrive and
hepatic insulin resistance that typify obese subjects with
the metabolic syndrome. NPY receptor (ant)agonists
and/or drugs that act to reduce sympathetic inputs to the
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